TY  - JOUR
AU  - Haist, Maximilian
AU  - Stege, Henner
AU  - Rogall, Friederike
AU  - Tan, Yuqi
AU  - von Wasielewski, Imke
AU  - Klespe, Kai Christian
AU  - Meier, Friedegund
AU  - Mohr, Peter
AU  - Kähler, Katharina C
AU  - Weichenthal, Michael
AU  - Hauschild, Axel
AU  - Schadendorf, Dirk
AU  - Ugurel, Selma
AU  - Lodde, Georg
AU  - Zimmer, Lisa
AU  - Gutzmer, Ralf
AU  - Debus, Dirk
AU  - Schilling, Bastian
AU  - Kreuter, Alexander
AU  - Ulrich, Jens
AU  - Meiss, Frank
AU  - Herbst, Rudolf
AU  - Forschner, Andrea
AU  - Leiter, Ulrike
AU  - Pfoehler, Claudia
AU  - Kaatz, Martin
AU  - Ziller, Fabian
AU  - Hassel, Jessica C
AU  - Tronnier, Michael
AU  - Sachse, Michael
AU  - Dippel, Edgar
AU  - Terheyden, Patrick
AU  - Berking, Carola
AU  - Heppt, Markus V
AU  - Kiecker, Felix
AU  - Haferkamp, Sebastian
AU  - Gebhardt, Christoffer
AU  - Simon, Jan Christoph
AU  - Grabbe, Stephan
AU  - Loquai, Carmen
TI  - Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG.
JO  - Journal for ImmunoTherapy of Cancer
VL  - 11
IS  - 9
SN  - 2051-1426
CY  - London
PB  - BioMed Central
M1  - DKFZ-2023-01906
SP  - e007630
PY  - 2023
AB  - Adjuvant therapy with immune-checkpoint inhibitors (CPI) or BRAF/MEK-directed targeted therapy (TT) improves recurrence-free survival (RFS) for patients with advanced, BRAFV600-mutant (BRAFmut) resected melanoma. However, 40
KW  - Adjuvant Drug Therapy (Other)
KW  - Immune Checkpoint Inhibitors (Other)
KW  - Melanoma (Other)
KW  - Molecular Targeted Therapy (Other)
KW  - Recurrence (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37730278
DO  - DOI:10.1136/jitc-2023-007630
UR  - https://inrepo02.dkfz.de/record/282917
ER  -